Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.01
+0.83%
HEALTHCARE · Cap: $6.01B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+2.04%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 455% more annual revenue ($17.32B vs $3.12B). AMRX leads profitability with a 5.0% profit margin vs 4.1%. AMRX trades at a lower P/E of 35.9x. AMRX earns a higher WallStSmart Score of 56/100 (C).
AMRX
Buy56
out of 100
Grade: C
TEVA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.5%
Fair Value
$20.56
Current Price
$17.01
$3.55 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 157.1% YoY
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
5.0% margin — thin
Trading at 170.1x book value
ROE of -881.0% — below average capital efficiency
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
The strongest argument for AMRX centers on EPS Growth.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : AMRX
The primary concerns for AMRX are P/E Ratio, Profit Margin, Price/Book. Debt-to-equity of 84.54 is elevated, increasing financial risk.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMRX carries more volatility with a beta of 1.24 — expect wider price swings.
AMRX is growing revenue faster at 9.9% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AMRX scores higher overall (56/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?